<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949130</url>
  </required_header>
  <id_info>
    <org_study_id>NXL103/2002</org_study_id>
    <nct_id>NCT00949130</nct_id>
  </id_info>
  <brief_title>Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)</brief_title>
  <official_title>A Multicenter,Investigator-blinded,Randomized, Comparative Study to Evaluate the Efficacy and Safety of Oral NXL103 Versus Oral Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novexel Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novexel Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of oral NXL103 vs.
      established treatment of acute bacterial infection in adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response at the early follow-up visit (Test of cure)</measure>
    <time_frame>7 days post therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome at the late follow-up visit</measure>
    <time_frame>21 days post therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome at the end of treatment</measure>
    <time_frame>10-14 days therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological outcome at the early follow-up visit (Test of cure)</measure>
    <time_frame>7 days post-therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profiles (safety and tolerability)</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population pharmacokinetic profile of the experimental study drug</measure>
    <time_frame>Day 1-5 while on study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Acute Bacterial Skin and Skin Structure Infections</condition>
  <arm_group>
    <arm_group_label>NXL103</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BID for 7-14 days orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linezolid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BID for 7-14 days orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NXL103</intervention_name>
    <description>BID for 7-14 days</description>
    <arm_group_label>NXL103</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>BID for 7-14 days</description>
    <arm_group_label>Linezolid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with acute bacterial skin and skin structure infection (ABSSSI) with at
             least 3 signs or symptoms

        Exclusion Criteria:

          -  Uncomplicated acute bacterial skin and skin structure infections

          -  ABSSSI suspected or proven to be due to Gram negative and/or anaerobic pathogens

          -  Pregnant or lactating women

          -  Inadequately controlled diabetes mellitus

          -  Inadequately controlled arterial hypertension

          -  Moderate-to-severe renal impairment

          -  Moderate-to-severe liver disease

          -  Conditions associated with immunodeficiency

          -  Known hypersensitivity or any contraindication for the use of any of the 2 study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kuligowski, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novexel Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sharp Chula Vista Research Office</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fountain Valley Regional Hospital and Medical Center</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Grossmont Research Office</name>
      <address>
        <city>LaMesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-City Oceanside Office</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Regional Research Group</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Regional Research Group</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho Falls Infectious Diseases</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseaes MPLS-LTD</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercury Street Medical Group</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RPS Infectious Diseases</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roosevelt Hospital</name>
      <address>
        <city>Guatemala</city>
        <zip>1011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNICAR</name>
      <address>
        <city>Guatemala</city>
        <zip>1011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Health Center</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Hospital</name>
      <address>
        <city>Quetzaltenango</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guatemala</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2009</study_first_posted>
  <last_update_submitted>March 17, 2010</last_update_submitted>
  <last_update_submitted_qc>March 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Michael Kuligowski, Director of Clinical Research</name_title>
    <organization>Novexel Inc</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Streptogramin A</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 17, 2011</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>July 6, 2011</submitted>
    <submission_canceled>Unknown</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

